TG on go with U.S. application for umbralisib in MZL

Based on FDA feedback, TG Therapeutics (TGTX +0.3%) expects to file a U.S. marketing application seeking accelerated approval to use umbralisib to treat marginal zone lymphoma (MZL) by year-end.

The data supporting the application was generated in the Phase 2b UNITY-NHL study.

https://seekingalpha.com/news/3470450-tg-go-u-s-application-umbralisib-mzl